Navigation Links
Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
Date:3/28/2011

mpletion of the Offer; and(C)

without limiting any of the foregoing, no Regulatory Authority becomes entitled to suspend, terminate or withhold any grant, development assistance or other financial assistance to which any member of the ChemGenex Group is or may be otherwise entitled or to require or accelerate repayment of any grant, development assistance or other financial assistance previously provided to any member of the ChemGenex Group.(d)

HSRNo objection being received and the period of 30 days expiring (or earlier terminated) from the date of the filing by Cephalon CXS of a merger / acquisition notification as required under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.(e)

No prescribed occurrences(i)

Between the time beginning when the Bidder's Statement is given to ChemGenex and ending at the end of the Offer Period, none of the following occurrences happens:(A)

ChemGenex converts all or any of the ChemGenex Shares into a larger or smaller number of ChemGenex Shares;(B)

any member of the ChemGenex Group resolves to reduce its share capital in any way;(C)

any member of the ChemGenex Group enters into a buy-back agreement or resolves to approve the terms of a buy-back agreement under section 257C(1) or 257D(1) of the Corporations Act; (D)

any member of the ChemGenex Group issues shares (other than pursuant to Disclosed Options or the convertible notes on issue to Cephalon International) or grants an option over its shares, or agrees to make such an issue or grant such an option; (E)

any member of the ChemGenex Group issues, or agrees to issue, convertible notes;(F)

any member of the ChemGenex Group disposes, or agrees to dispose, of the whole, or a substantial part, of its business or property;(G)

any member of the ChemGenex Group charges, or agrees to charge, the whole, or a substantial part, of its business or property;(H)

any member of the C
'/>"/>

SOURCE Cephalon, Inc.; ChemGenex Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Cephalon Announces Definitive Agreement to Acquire Gemin X
3. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
4. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
5. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
6. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
7. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
8. Cephalon to Webcast Investor Day
9. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
10. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
11. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... LEIDEN, The Netherlands, July 6 Three ... Therapeutics and InteRNA,Technologies - have joined public-private partnership TI ... on cancer and,inflammatory diseases, have a total budget of ... The new consortium, formed by Syncom, Synvolux Therapeutics, and,University ...
... , NEW YORK, June 30 Betsy McCaughey of the Committee ... hospital infection rates made available by the NYS Department of Health ... have the lowest infection rates - and steer clear of those ... , Betsy McCaughey, a Ph.D., founded RID in 2004 with a ...
Cached Medicine Technology:New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:9/30/2014)... Keystone Symposia will convene the first conference of ... Global Health Series on "The Modes of Action ... immediately following the conclusion of the Grand Challenges Meeting ... of the Keystone Symposia Global Health Series, supported by ... funded travel awards for 36 investigators from developing countries ...
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... Calif., Sept. 30, 2014 Research by UC Irvine ... functions, shedding light on a vital process that determines ... In the online version of Nature Immunology , ... and other Institute for Immunology colleagues describe a critical ... released into the bloodstream. , A T cell is ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... by Blue Star Nutraceuticals designed to help maximize lean, ... that optimizes the body’s absorption of glucose has caught ... , “The main purpose behind Glycodrive is to ... builds lean muscle,” reports Michaels. “Carbs are essential in ...
(Date:9/30/2014)... 30, 2014 Elevate , the latest ... better in and out of the gym by providing natural ... the attention of Shane Michaels, prompting an investigative review. ... the reason most people simply just don’t have the ability ... focused at work, getting the motivation to finish a project, ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... Authorizations and Reduces DenialsGREENWOOD VILLAGE, Colo., March 25 ... cycle solutions for the healthcare industry, today announced ... and denial prevention product for hospitals. Missing authorizations ... 15 percent of all payer-denied claims, and can ...
... Inc., the largest privately held spinal implant manufacturer ... MicroFuse(TM) ST Granules, a unique resorbable polymer bone ... MicroFuse(TM) technology utilizes proprietary combinations of poly (lactic ... patented microsphere process to deliver up to twelve ...
... 50 raises odds almost 4-fold , , WEDNESDAY, March 25 (HealthDay ... fourfold increased risk of melanoma in women under the age ... York University School of Medicine. , Identification of this variation ... test to identify women at high risk for the deadly ...
... ACell, Inc. and its founder, Alan Spievack, MD, ... Spievack described how his severed finger grew back after ... technology is a naturally occurring bioscaffold derived from porcine ... it is resorbed and replaced with new native tissue ...
... Dr. Ching-Hua Wang, Chair of Biology, Geology and Nursing, ... California State University Channel Islands , was recently awarded ... Medicine (CIRM) as a part of their Bridges to Stem ... to receive funding from the program. , , ...
... "Today was a monumental day on Capitol Hill ... long-term services and supports.We commend the Senate Finance Committee ... in this year,s health care reform. Long-term services and ... America,s health care crisis. The needs are great. The ...
Cached Medicine News:Health News:Recondo Technology Announces Authorization and Denial Prevention Software Service 2Health News:Globus Medical's MicroFuse(TM) Technology Engineered for Optimal Strength and Porosity 2Health News:Gene Test May ID Younger Women at Risk for Melanoma 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 3Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 2Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 3
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and negative ... inoculation. With these slides, perform QC and ... enhance their education and training programs by ... interpretation, all on one slide! KWIK-QC slides ...
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population....
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: